Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01114204




Registration number
NCT01114204
Ethics application status
Date submitted
29/04/2010
Date registered
3/05/2010
Date last updated
21/04/2022

Titles & IDs
Public title
A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia
Scientific title
A Phase III, Randomized, Open-label, Active-Controlled, Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia
Secondary ID [1] 0 0
AMAG-FER-IDA-302
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Iron Deficiency Anemia 0 0
Condition category
Condition code
Blood 0 0 0 0
Anaemia
Diet and Nutrition 0 0 0 0
Other diet and nutrition disorders
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ferumoxytol
Treatment: Drugs - Iron Sucrose

Experimental: Ferumoxytol - Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters \[mL\]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).

Active comparator: Iron Sucrose - Participants received an IV injection or infusion of iron sucrose 200 mg (10 mL) on Day 1 (Baseline) and on 4 other non-consecutive days over a 14-day period, for a total cumulative dose of 1.0 g. Participants receiving their first ever exposure to IV iron sucrose, received a test dose on Day 1 prior to receiving the remainder of the first dose, as prescribed in the package insert for some countries.


Treatment: Drugs: Ferumoxytol
IV Ferumoxytol

Treatment: Drugs: Iron Sucrose
IV Iron Sucrose
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Participants Who Achieved A =2.0 g/dL Increase In Hemoglobin At Any Time From Baseline To Week 5
Timepoint [1] 0 0
Baseline (Day 1) through Week 5
Secondary outcome [1] 0 0
Mean Change In Hemoglobin From Baseline To Week 5
Timepoint [1] 0 0
Baseline (Day 1), Week 5
Secondary outcome [2] 0 0
Participants Achieving A Hemoglobin Level =12.0 g/dL At Any Time From Baseline To Week 5
Timepoint [2] 0 0
Baseline (Day 1) through Week 5
Secondary outcome [3] 0 0
Mean Change In TSAT From Baseline To Week 5
Timepoint [3] 0 0
Baseline (Day 1), Week 5
Secondary outcome [4] 0 0
Mean Change In Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score From Baseline To Week 5
Timepoint [4] 0 0
Baseline (Day 1), Week 5
Secondary outcome [5] 0 0
Time To Hemoglobin Increase Of =2.0 g/dL Or Hemoglobin Value Of =12.0 g/dL From Baseline
Timepoint [5] 0 0
From Baseline (Day 1) up to Week 5

Eligibility
Key inclusion criteria
Key Inclusion Criteria include:

1. Males and females =18 years of age
2. Participants with IDA defined as having:

1. Hemoglobin <10.0 g/deciliter (dL)
2. Transferrin saturation (TSAT) <20%
3. Participants who have a history of unsatisfactory oral iron therapy or in whom oral iron cannot be used
4. Female participants of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to screening and agree to remain on birth control until completion of participation in the study

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria include:

1. History of allergy to IV iron
2. Allergy to two or more classes of drugs
3. Participants on dialysis or with an estimated glomerular filtration rate <30 mL/minute(min)/1.73 square meter (m^2)
4. Female participants who are pregnant, intend to become pregnant, are breastfeeding, within 2 weeks postpartum, or have a positive serum/urine pregnancy test
5. Hemoglobin =7.0 g/dL
6. Serum ferritin >600 nanogram/mL

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/08/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
25/06/2012
Sample size
Target
Accrual to date
Final
605
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Adelaide
Recruitment hospital [2] 0 0
For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Ballarat
Recruitment hospital [3] 0 0
For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Concord
Recruitment hospital [4] 0 0
For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Five Dock
Recruitment hospital [5] 0 0
For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Gosford
Recruitment hospital [6] 0 0
For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Kingswood
Recruitment hospital [7] 0 0
For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Parkville
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Ballarat
Recruitment postcode(s) [3] 0 0
- Concord
Recruitment postcode(s) [4] 0 0
- Five Dock
Recruitment postcode(s) [5] 0 0
- Gosford
Recruitment postcode(s) [6] 0 0
- Kingswood
Recruitment postcode(s) [7] 0 0
- Parkville
Recruitment outside Australia
Country [1] 0 0
France
State/province [1] 0 0
La Tronche
Country [2] 0 0
Germany
State/province [2] 0 0
Berlin
Country [3] 0 0
Germany
State/province [3] 0 0
Frankfurt
Country [4] 0 0
Germany
State/province [4] 0 0
Mainz
Country [5] 0 0
Germany
State/province [5] 0 0
Siegen
Country [6] 0 0
Germany
State/province [6] 0 0
Wilhelmshaven
Country [7] 0 0
Hungary
State/province [7] 0 0
Békéscsaba
Country [8] 0 0
Hungary
State/province [8] 0 0
Gyula
Country [9] 0 0
Hungary
State/province [9] 0 0
Komárom
Country [10] 0 0
Hungary
State/province [10] 0 0
Miskolc
Country [11] 0 0
Hungary
State/province [11] 0 0
Szekszárd
Country [12] 0 0
Hungary
State/province [12] 0 0
Szolnok
Country [13] 0 0
Hungary
State/province [13] 0 0
Vác
Country [14] 0 0
Hungary
State/province [14] 0 0
Zalaegerszeg
Country [15] 0 0
Italy
State/province [15] 0 0
Padova
Country [16] 0 0
Italy
State/province [16] 0 0
Rozzano
Country [17] 0 0
Korea, Republic of
State/province [17] 0 0
Cheonan
Country [18] 0 0
Korea, Republic of
State/province [18] 0 0
Daegu
Country [19] 0 0
Korea, Republic of
State/province [19] 0 0
Incheon
Country [20] 0 0
Korea, Republic of
State/province [20] 0 0
Seoul
Country [21] 0 0
Korea, Republic of
State/province [21] 0 0
Suwon
Country [22] 0 0
Latvia
State/province [22] 0 0
Daugavpils
Country [23] 0 0
Latvia
State/province [23] 0 0
Riga
Country [24] 0 0
Latvia
State/province [24] 0 0
Ventspils
Country [25] 0 0
Lithuania
State/province [25] 0 0
Kaunas
Country [26] 0 0
Lithuania
State/province [26] 0 0
Klaipeda
Country [27] 0 0
Lithuania
State/province [27] 0 0
Vilnius
Country [28] 0 0
Lithuania
State/province [28] 0 0
Šiauliai
Country [29] 0 0
Poland
State/province [29] 0 0
Bialystok
Country [30] 0 0
Poland
State/province [30] 0 0
Katowice
Country [31] 0 0
Poland
State/province [31] 0 0
Kraków
Country [32] 0 0
Poland
State/province [32] 0 0
Sopot
Country [33] 0 0
Poland
State/province [33] 0 0
Warszawa
Country [34] 0 0
Poland
State/province [34] 0 0
Wroclaw
Country [35] 0 0
Poland
State/province [35] 0 0
Zgierz
Country [36] 0 0
Poland
State/province [36] 0 0
Leczyca
Country [37] 0 0
Romania
State/province [37] 0 0
Brasov
Country [38] 0 0
Romania
State/province [38] 0 0
Bucharest
Country [39] 0 0
Romania
State/province [39] 0 0
Iasi
Country [40] 0 0
Romania
State/province [40] 0 0
Suceava
Country [41] 0 0
Romania
State/province [41] 0 0
Timisoara
Country [42] 0 0
Romania
State/province [42] 0 0
Târgu-Mures
Country [43] 0 0
South Africa
State/province [43] 0 0
Cape Town
Country [44] 0 0
South Africa
State/province [44] 0 0
Durban
Country [45] 0 0
South Africa
State/province [45] 0 0
Roodepoort
Country [46] 0 0
South Africa
State/province [46] 0 0
Stellenbosch
Country [47] 0 0
Spain
State/province [47] 0 0
Barcelona
Country [48] 0 0
Spain
State/province [48] 0 0
Manresa
Country [49] 0 0
Spain
State/province [49] 0 0
Santa Cruz De Tenerife
Country [50] 0 0
Spain
State/province [50] 0 0
Sevilla
Country [51] 0 0
Ukraine
State/province [51] 0 0
Cherkasy
Country [52] 0 0
Ukraine
State/province [52] 0 0
Chernivtsi
Country [53] 0 0
Ukraine
State/province [53] 0 0
Donetsk
Country [54] 0 0
Ukraine
State/province [54] 0 0
Ivano-Frankivsk
Country [55] 0 0
Ukraine
State/province [55] 0 0
Kyiv
Country [56] 0 0
Ukraine
State/province [56] 0 0
Odessa
Country [57] 0 0
Ukraine
State/province [57] 0 0
Simferopol
Country [58] 0 0
Ukraine
State/province [58] 0 0
Vinnytsya
Country [59] 0 0
Ukraine
State/province [59] 0 0
Zaporizhzhya
Country [60] 0 0
United Kingdom
State/province [60] 0 0
Cambridge
Country [61] 0 0
United Kingdom
State/province [61] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AMAG Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01114204